Update: A shining start to 2016
Skyepharma ended 2015 with a flurry of positive news. The partnering deal with Mundipharma for SKP-2076, Pacira’s announcement of a resolution achieved with the FDA on Exparel coupled with an encouraging FY15 pre-close update marks a good start for 2016. Skyepharma has entered into a feasibility and option agreement for SKP-2076 with Mundipharma, the partner of choice in our view, and the timely announcement could ensure seamless development once SKP-2076 feasibility studies complete by mid-2016. Meanwhile, the FDA has formally rescinded a warning letter issued to Pacira on US Exparel marketing and, importantly, also broadened the Exparel label significantly.Skyland Petroleum is engaged in the licensing of copyright for feature films.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.